{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:48:12Z","timestamp":1781801292256,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:00:00Z","timestamp":1731715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Systemic lupus erythematosus (SLE) has a non-uniform course directly reflected in changes in disease activity and anticipation of damage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>To determine the impact of disease activity at the onset of disease diagnosis, measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) disease activity score, on different disease parameters and outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This multicentre, retrospective cohort study included 823 SLE patients. Disease damage was measured by the Systemic Lupus International Collaborating Clinics Damage Index (SLICC), and comorbidities were measured by the Charlson Comorbidity Index (CCI). According to the mean SLEDAI at onset of disease diagnosis, patients were classified into two groups: I included patients with a mean SLEDAI\u2009\u2264\u200910 (non-severe disease activity), and II included patients with a mean SLEDAI\u2009&gt;\u200910 (severe disease activity).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>SLEDAI at onset of disease diagnosis was a predictor of damage and comorbidities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>A higher SLEDAI score at onset of disease diagnosis was associated with damage accrual. Patients who are younger at disease onset are more likely to have more severe disease. Severe disease activity at the onset of disease diagnosis was also associated with future comorbidity occurrences, but it was not significantly associated with mortality. SLEDAI at the onset of disease diagnosis could be a prognostic marker predicting the damage, which may help in the identification of patients who are at higher risk of adverse outcomes. Special care should be directed towards patients who are younger at disease onset as they may have a higher disease activity at diagnosis.\n<jats:table-wrap>\n                <jats:table>\n                  <jats:tbody>\n                    <jats:tr>\n                      <jats:td align=\"left\" colspan=\"2\">\n                        <jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>This is a unique study as it is the first to focus on the impact of SLE disease activity at the onset of disease diagnosis measured by SLEDAI disease activity score on different disease parameters and outcomes.<\/jats:italic>\u2022 <jats:italic>Previous studies, though these are scarce, have highlighted the impact of disease activity throughout the disease course and not specifically at the beginning of the SLE disease.<\/jats:italic>\n                      <\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody>\n                <\/jats:table>\n              <\/jats:table-wrap>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10067-024-07222-w","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T00:29:48Z","timestamp":1731716988000},"page":"229-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Disease activity at the onset of diagnosis as a predictor of disease outcomes in a cohort of patients with systemic lupus erythematosus: A post hoc retrospective analysis of the COMOSLE-EGYPT study"],"prefix":"10.1007","volume":"44","author":[{"given":"Abir","family":"Mokbel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermeen A.","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9580-9165","authenticated-orcid":false,"given":"Alkhateeb","family":"Alkemary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Abdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,16]]},"reference":[{"key":"7222_CR1","unstructured":"Ehrenstein MR, Isenberg DA (2004) Systemic lupus erythematosus in adults-clinical feature and aetiopathogenesis In: Isenberg DA, Maddison PJ, Woo P, et al, (eds) Oxford textbook of rheumatology. 3rd edn. Oxford: Oxford University Press"},{"key":"7222_CR2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nrrheum.2014.118","volume":"10","author":"K Franklyn","year":"2014","unstructured":"Franklyn K, Hoi A, Nikpour M et al (2014) The need to define treatment goals for systemic lupus erythematosus. Nat Rev Rheumatol 10:567\u2013571","journal-title":"Nat Rev Rheumatol"},{"key":"7222_CR3","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","volume":"393","author":"L Durcan","year":"2019","unstructured":"Durcan L, O\u2019Dwyer T, Petri M (2019) Management strategies and future directions for systemic lupus erythematosus in adults. Lancet 393:2332\u20132343","journal-title":"Lancet"},{"key":"7222_CR4","doi-asserted-by":"publisher","first-page":"e000303","DOI":"10.1136\/lupus-2018-000303","volume":"6","author":"R Felten","year":"2019","unstructured":"Felten R, Sagez F, Gavand P-E et al (2019) 10 most important contemporary challenges in the management of SLE. Lupus Sci Med 6:e000303","journal-title":"Lupus Sci Med"},{"key":"7222_CR5","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","volume":"393","author":"T D\u00f6rner","year":"2019","unstructured":"D\u00f6rner T, Furie R (2019) Novel paradigms in systemic lupus erythematosus. Lancet 393:2344\u201358","journal-title":"Lancet"},{"issue":"6","key":"7222_CR6","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF Van Vollenhoven","year":"2014","unstructured":"Van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73(6):958\u2013967","journal-title":"Ann Rheum Dis"},{"key":"7222_CR7","doi-asserted-by":"publisher","first-page":"e000287","DOI":"10.1136\/lupus-2018-000287","volume":"5","author":"I Giannakou","year":"2018","unstructured":"Giannakou I, Chatzidionysiou K, Magder L, Gy\u00f6ri N, van Vollenhoven R, Petri M (2018) Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. Lupus Sci Med 5:e000287. https:\/\/doi.org\/10.1136\/lupus-2018-000287","journal-title":"Lupus Sci Med"},{"key":"7222_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-68566-3","volume-title":"Primer on the rheumatic diseases","author":"JH Klippel","year":"2008","unstructured":"Klippel JH (2008) Primer on the rheumatic diseases, 13th edn. Springer, New York, NY","edition":"13"},{"key":"7222_CR9","doi-asserted-by":"crossref","unstructured":"Iaccarino L, Larosa M, Doria A (2016) Disease activity indices and prognosis of systemic lupus erythematosus. In: Roccatello D, Emmi L (eds) Connective tissue disease: a comprehensive guide-volume 1, Rare diseases of the immune system. Springer, Cham. Springer International Publishing Switzerland 199","DOI":"10.1007\/978-3-319-24535-5_15"},{"key":"7222_CR10","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1177\/0961203310366572","volume":"19","author":"J Nossent","year":"2010","unstructured":"Nossent J, Kiss E, Rozman B et al (2010) Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 19:949\u2013956","journal-title":"Lupus"},{"key":"7222_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/01.md.0000224709.70133.f7","volume":"85","author":"N Kasitanon","year":"2006","unstructured":"Kasitanon N, Magder LS, Petri M (2006) Predictors of survival in systemic lupus erythematosus. Medicine 85:147\u2013156","journal-title":"Medicine"},{"key":"7222_CR12","first-page":"174239532211389","volume":"13","author":"SM Gamal","year":"2022","unstructured":"Gamal SM, Mokbel A, Niazy MH, Elgengehy FT, Elsaid NY, Fouad NA et al (2022) Comorbidities among Egyptian systemic lupus erythematosus: the COMOSLEEGYPT study. Chronic Illn 13:17423953221138920","journal-title":"Chronic Illn"},{"issue":"9","key":"7222_CR13","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725","journal-title":"Arthritis Rheum"},{"issue":"6","key":"7222_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630\u201340","journal-title":"Arthritis Rheum"},{"issue":"3","key":"7222_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39(3):363\u2013369","journal-title":"Arthritis Rheum"},{"key":"7222_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"7222_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/ard.2007.070367","volume":"67","author":"G Bertsias","year":"2008","unstructured":"Bertsias G, Ioannidis JPA, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195\u2013205","journal-title":"Ann Rheum Dis"},{"key":"7222_CR18","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/ard.2009.117200","volume":"69","author":"M Mosca","year":"2010","unstructured":"Mosca M, Tani C, Aringer M et al (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and observational studies. Ann Rheum Dis 69:1269\u20131274","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 85","key":"7222_CR19","first-page":"S-85","volume":"32","author":"I Castrej\u00f3n","year":"2014","unstructured":"Castrej\u00f3n I, Tani C, Jolly M, Huang A, Mosca M (2014) Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin Exp Rheumatol. 32(5 Suppl 85):S-85-95","journal-title":"Clin Exp Rheumatol."},{"issue":"Suppl 11","key":"7222_CR20","first-page":"S37","volume":"63","author":"J Romero-Diaz","year":"2011","unstructured":"Romero-Diaz J, Isenberg D, Ramsey-Goldman R (2011) Measures of adult systemic lupus erythematosus. Arthritis Care Res (Hoboken) 63(Suppl 11):S37-46","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"7222_CR21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.berh.2005.03.010","volume":"19","author":"B Griffiths","year":"2005","unstructured":"Griffiths B, Mosca M, Gordon C (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19(5):685\u2013708","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"7222_CR22","first-page":"541","volume":"10","author":"C Vitali","year":"1992","unstructured":"Vitali C, Bencivelli W, Isenberg D, Smolen J, Snaith M, Sciuto M (1992) The European Consensus Study Group for Disease Activity in SLE. Disease activity in systemic lupus erythematosus: report of the consensus study group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 10:541\u20137","journal-title":"Clin Exp Rheumatol"},{"key":"7222_CR23","unstructured":"Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D, Kalunian K, Liang MH, Maddison P, Nived O, et al (1994) Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 21(8):1468-71 & (Koichiro Ohmura (2021) Which is the best SLE activity index for clinical trials? Mod Rheumatol, 31:1, 20-28"},{"key":"7222_CR24","first-page":"e000372","volume":"7","author":"R Koelmeyer","year":"2020","unstructured":"Koelmeyer R, Nim HT, Nikpour M et al (2020) High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus Lupus. Sci Med 7:e000372","journal-title":"Sci Med"},{"key":"7222_CR25","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","volume":"71","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Petri MA, Cervera R et al (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71:1343\u20131349","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7222_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13075-021-02572-1","volume":"23","author":"A Hoi","year":"2021","unstructured":"Hoi A, Koelmeyer R, Bonin J, Sun Y, Kao A, Gunther O, Nim HT, Morand E (2021) Disease course following high disease activity status revealed patterns in SLE. Arthritis Res Ther 23(1):191","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"7222_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.12669\/pjms.36.3.1480","volume":"36","author":"R Shamim","year":"2020","unstructured":"Shamim R, Farman S, Batool S, Khan SEA, Raja MKH (2020) Association of systemic lupus erythematosus disease activity index score with clinical and laboratory parameters in pediatric-onset systemic lupus erythematosus. Pak J Med Sci 36(3):467\u2013472","journal-title":"Pak J Med Sci"},{"issue":"1","key":"7222_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0049-0172(05)80023-X","volume":"23","author":"JC Nossent","year":"1993","unstructured":"Nossent JC (1993) Course and prognostic value of systemic lupus erythematosus disease activity index in black Caribbean patients. Semin Arthritis Rheum 23(1):16\u201321","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"7222_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/annrheumdis-2012-202443","volume":"73","author":"A Doria","year":"2012","unstructured":"Doria A, Amoura Z, Cervera R, Khamastha MA, Schneider M, Richter J, Guillemin F, Kobelt G, Maurel F, Garofano A, Perna A, Murray M, Schmitt C, Boucot I (2012) Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis 73(1):154\u201360. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202443","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"7222_CR30","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.autrev.2015.02.008","volume":"14","author":"F Ceccarelli","year":"2015","unstructured":"Ceccarelli F, Perricone C, Massaro L, Cipriano E, Alessandri C, Spinelli FR, Valesini G, Conti F (2015) Assessment of disease activity in systemic lupus erythematosus: lights and shadows. Autoimmun Rev 14(7):601\u2013608","journal-title":"Autoimmun Rev"},{"key":"7222_CR31","first-page":"664","volume":"27","author":"MM Ward","year":"2000","unstructured":"Ward MM, Marx AS, Barry NN (2000) Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 27:664\u2013670","journal-title":"J Rheumatol"},{"key":"7222_CR32","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1136\/ard.2007.070847","volume":"67","author":"CS Yee","year":"2008","unstructured":"Yee CS, Isenberg DA, Prabu A, Sokoll K, Teh LS, Rahman A et al (2008) BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis 67:873\u2013876","journal-title":"Ann Rheum Dis"},{"key":"7222_CR33","first-page":"1570","volume":"33","author":"A Becker-Merok","year":"2008","unstructured":"Becker-Merok A, Nossent HC (2008) Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 33:1570\u20131577","journal-title":"J Rheumatol"},{"issue":"7","key":"7222_CR34","first-page":"1265","volume":"22","author":"M Abu-Shakra","year":"1995","unstructured":"Abu-Shakra M, Urowitz MB, Gladman DD, Gough J (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 22(7):1265\u20131270","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07222-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T13:39:59Z","timestamp":1736775599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07222-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,16]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["7222"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07222-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,16]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}